KRAEFTENS BEKAEMPELSE

Their core work

The Danish Cancer Society (Kræftens Bekæmpelse) is Denmark's leading cancer research and patient advocacy organization. They conduct translational cancer research spanning molecular biology, epidemiology, and clinical survivorship, while also driving public health campaigns and patient support programs. In EU projects, they contribute cancer biology expertise, large-scale epidemiological data, and clinical insights — particularly around personalized medicine, childhood cancer survivorship, and environmental exposure risks.

What they specialise in

How they've shifted over time

Their early H2020 work (2014–2018) concentrated on fundamental cancer biology through training networks — melanoma translational research and synthetic lethality mechanisms. From 2019 onward, the focus shifted markedly toward applied and patient-facing themes: survivorship care for childhood cancer survivors, environmental exposure epidemiology, and AI-powered personalized medicine. This trajectory shows a clear move from basic cancer science toward clinical application, data-driven decision-making, and long-term patient outcomes.

DCS is moving toward data-intensive, AI-supported clinical oncology and survivorship research — future partners should expect interest in computational approaches, real-world patient data, and personalized treatment strategies.

How they like to work

Primarily a consortium partner (6 of 7 projects), contributing domain expertise rather than leading large initiatives. Their single coordination role was a focused Marie Curie fellowship (rDNAstress), suggesting they coordinate smaller, specialist projects while joining larger consortia as expert contributors. With 130 unique partners across 27 countries, they maintain a wide European network and are comfortable working in diverse, multinational teams.

An extensive network of 130 unique partners spanning 27 countries, indicating deep pan-European connectivity. As a major national cancer society, they are well-positioned to bridge clinical, epidemiological, and academic cancer research communities across Europe.

What sets them apart

DCS combines the scale and data assets of a national cancer society — including population-level registries and patient cohorts — with active EU research participation. Unlike university labs focused purely on bench science, they bring patient advocacy, public health infrastructure, and real-world clinical data to consortia. Their dual expertise in both molecular oncology and long-term survivorship epidemiology makes them a versatile partner for projects spanning the full cancer research pipeline.

Highlights from their portfolio

• DECIDER
  Their largest project (EUR 1.35M) combining AI, data analytics, and software engineering with clinical oncology to tackle chemotherapy resistance — a significant investment signaling their strategic direction.
• PanCareFollowUp
  Addresses an underserved area — long-term survivorship care for childhood cancer survivors — combining clinical guidelines with lifestyle interventions across European healthcare systems.
• rDNAstress
  Their only coordinated project, a Marie Curie fellowship investigating DNA damage mechanisms in the nucleolus with implications for genome stability and cancer.